PMID- 37337388
OWN - NLM
STAT- MEDLINE
DCOM- 20231023
LR  - 20231025
IS  - 2192-2659 (Electronic)
IS  - 2192-2640 (Linking)
VI  - 12
IP  - 26
DP  - 2023 Oct
TI  - Sublingual Dissolving Microneedle (SLDMN)-Based Vaccine for Inducing Mucosal 
      Immunity against SARS-CoV-2.
PG  - e2300889
LID - 10.1002/adhm.202300889 [doi]
AB  - The coronavirus pandemic has accelerated the development of next-generation 
      vaccination technology to combat future pandemic outbreaks. Mucosal vaccination 
      effectively protects the mucosal surfaces, the primary sites of viral entry, by 
      inducing the secretion of immunoglobulin A (IgA) and humoral IgG. Here, a 
      dissolving microneedle (DMN) is adopted as a mucosal vaccine delivery platform to 
      directly penetrate the sublingual site, which is rich in antigen-presenting cells 
      (APCs) and lymphoid tissues. The sublingual dissolving microneedle (SLDMN) 
      vaccination platform comprised a micropillar-based compartment and a 3D-printed 
      SLDMN applicator as a substitute for the DMN patch. The penetration efficacy of 
      SLDMNs is assessed using in vitro optical coherence tomography (OCT) and in vivo 
      histological analysis. The efficacy of SLDMN is also evaluated in a vaccine form 
      using the recombinant spike (S1) protein of the severe acute respiratory syndrome 
      coronavirus 2 (SARS-CoV-2). Furthermore, SLDMN is used to challenge transgenic 
      mice expressing human angiotensin-converting enzyme 2 (hACE2) receptors. Its 
      effects are evaluated on antibody production, survival rate, and inflammation 
      attenuation after infection compared to the intramuscular (IM) injections. 
      Overall, SLDMN effectively induced mucosal immunity via IgA secretion, attenuated 
      lung inflammation, and lowered the levels of cytokines and chemokines, which may 
      prevent the "cytokine storm" after SARS-CoV-2 infection.
CI  - (c) 2023 Wiley-VCH GmbH.
FAU - Kim, Youseong
AU  - Kim Y
AD  - Department of Biotechnology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, 
      Seoul, 03722, Republic of Korea.
FAU - Park, In Ho
AU  - Park IH
AD  - Institute of Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
AD  - Severance Biomedical Science Institute, Yonsei University College of Medicine, 
      50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
FAU - Shin, Jiwoo
AU  - Shin J
AD  - Department of Biotechnology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, 
      Seoul, 03722, Republic of Korea.
FAU - Choi, Jaibyung
AU  - Choi J
AD  - Department of Biotechnology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, 
      Seoul, 03722, Republic of Korea.
FAU - Jeon, Chansol
AU  - Jeon C
AD  - JUVIC, 208Ho, 272, Digital-ro, Guro-gu, Seoul, 08389, Republic of Korea.
FAU - Jeon, Seonghun
AU  - Jeon S
AD  - Department of Biotechnology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, 
      Seoul, 03722, Republic of Korea.
FAU - Shin, Jeon-Soo
AU  - Shin JS
AD  - Department of Microbiology, Yonsei University College of Medicine, 50-1 
      Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
AD  - Institute of Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
AD  - Severance Biomedical Science Institute, Yonsei University College of Medicine, 
      50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
AD  - Brain Korea 21 Project for Medical Science, Yonsei University College of 
      Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
FAU - Jung, Hyungil
AU  - Jung H
AUID- ORCID: 0000-0002-1946-7300
AD  - Department of Biotechnology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, 
      Seoul, 03722, Republic of Korea.
AD  - JUVIC, 208Ho, 272, Digital-ro, Guro-gu, Seoul, 08389, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230706
PL  - Germany
TA  - Adv Healthc Mater
JT  - Advanced healthcare materials
JID - 101581613
RN  - 0 (Viral Vaccines)
RN  - 0 (Antibodies, Viral)
RN  - 0 (Immunoglobulin A)
SB  - IM
MH  - Mice
MH  - Animals
MH  - Humans
MH  - SARS-CoV-2
MH  - *Viral Vaccines
MH  - Antibodies, Viral
MH  - Immunity, Mucosal
MH  - *COVID-19/prevention & control
MH  - Immunoglobulin A/analysis
OTO - NOTNLM
OT  - SARS-CoV-2
OT  - dissolving microneedles
OT  - immunoglobulin A
OT  - mucosal immunity
OT  - sublingual microneedle vaccination
EDAT- 2023/06/20 06:41
MHDA- 2023/10/23 00:44
CRDT- 2023/06/20 00:53
PHST- 2023/06/07 00:00 [revised]
PHST- 2023/03/20 00:00 [received]
PHST- 2023/10/23 00:44 [medline]
PHST- 2023/06/20 06:41 [pubmed]
PHST- 2023/06/20 00:53 [entrez]
AID - 10.1002/adhm.202300889 [doi]
PST - ppublish
SO  - Adv Healthc Mater. 2023 Oct;12(26):e2300889. doi: 10.1002/adhm.202300889. Epub 
      2023 Jul 6.